Insider Trading Activity Edge Therapeutics, Inc. (NASDAQ:EDGE) – Insider Sold 7,500 shares of Stock

Insider Trading Activity For Edge Therapeutics, Inc. (NASDAQ:EDGE)

Brian A Leuthner , Insider of Edge Therapeutics, Inc. (NASDAQ:EDGE) reportedly Sold 7,500 shares of the company’s stock at an average price of 10.53 for a total transaction amount of $78,975.00 SEC Form

Insider Trading History For Edge Therapeutics, Inc. (NASDAQ:EDGE)

On 10/6/2015 James Healy, Director, bought 450,000 with an average share price of $11.00 per share and the total transaction amounting to $4,950,000.00.View SEC Filing

On 10/6/2015 Andrew J. Einhorn, CFO, bought 45,000 with an average share price of $11.00 per share and the total transaction amounting to $495,000.00.View SEC Filing

On 3/11/2016 James Healy, Director, bought 541,343 with an average share price of $7.30 per share and the total transaction amounting to $3,951,803.90.View SEC Filing

On 8/1/2016 Brian A Leuthner, Insider, sold 7,500 with an average share price of $9.54 per share and the total transaction amounting to $71,550.00.View SEC Filing

On 8/8/2016 W Bradford Middlekauff, VP, bought 10,000 with an average share price of $9.48 per share and the total transaction amounting to $94,800.00.View SEC Filing

On 10/3/2016 Brian A Leuthner, Insider, sold 7,500 with an average share price of $10.25 per share and the total transaction amounting to $76,875.00.View SEC Filing

On 12/1/2016 Brian A Leuthner, Insider, sold 7,500 with an average share price of $11.60 per share and the total transaction amounting to $87,000.00.View SEC Filing

Analyst Ratings For Edge Therapeutics, Inc. (NASDAQ:EDGE)
These are 1 Hold Rating, 1 Buy Rating .
The current consensus rating for Edge Therapeutics, Inc. (NASDAQ:EDGE) is Buy (Score: 2.50) with a consensus target price of $25.50 , a potential (146.14% upside)

Analyst Ratings History For Edge Therapeutics, Inc. (NASDAQ:EDGE)

• On 3/9/2016 JMP Securities Lower Price Target of rating Market Outperform with a price target of $34.00 to $18.00
• On 5/9/2016 Credit Suisse Group Lower Price Target of rating Outperform with a price target of $19.00 to $18.00
• On 3/3/2017 Guggenheim Reiterated Rating Buy to In-Line with a price target of $30.00
• On 3/3/2017 Leerink Swann Reiterated Rating Outperform to Outperform with a price target of $21.00

Recent Trading Activity for Edge Therapeutics, Inc. (NASDAQ:EDGE)
Shares of Edge Therapeutics, Inc. closed the previous trading session at 10.36 down -0.28 -2.63% with 70,444 shares trading hands.